Repeated enemas with hepatocyte growth factor selectively stimulate epithelial cell proliferation of injured mucosa in rats with experimental colitis

Life Sciences

Volumn 89, Issue 7-8, 2011, Pages 269-275

  Setoyama, Hitoshi ^a,b   Ido, Akio ^a,b   Numata, Masatsugu ^a,b   Moriuchi, Akihiro ^a,b   Yamaji, Naohisa ^a,b   Tamai, Tsutomu ^b   Funakawa, Keita ^b   Fujita, Hiroshi ^b   Sakiyama, Toshio ^b   Uto, Hirofumi ^b   Oketani, Makoto ^b   Tsubouchi, Hirohito ^a,b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cell proliferation; Experimental colitis; Hepatocyte growth factor; Inflammatory bowel disease; Intestinal mucosa

Indexed keywords

ENEMA; KI 67 ANTIGEN; RECOMBINANT SCATTER FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; COLITIS; COLON INJURY; COLON MUCOSA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; EXPERIMENTAL COLITIS; EXPERIMENTAL RAT; HISTOPATHOLOGY; INFLAMMATORY CELL; INTESTINE EPITHELIUM CELL; MALE; NONHUMAN; RAT; REPEAT PROCEDURE; SINGLE DRUG DOSE; TISSUE REGENERATION; TREATMENT DURATION;

ADMINISTRATION, RECTAL; ANIMALS; CELL PROLIFERATION; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; INTESTINAL MUCOSA; RATS; RECOMBINANT PROTEINS; TRINITROBENZENESULFONIC ACID;

RATTUS;

EID: 79961007492     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.06.019     Document Type: Article

References (38)

1. Baars JE, Looman CW, Steyerberg EW, Beukers R, Tan AC, Weusten RL, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2010;106:319-28.
2. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am J Gastroenterol 2006;101:1048-56. (Pubitemid 43725319)
3. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, et al. Lymphoploriferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancer 2009;374:1617-25.
4. Colombel JF, Loftus Jr EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31. (Pubitemid 38040720)
5. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
6. Dayharsh GA, Loftus Jr EV, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-7. (Pubitemid 34049196)
7. Domenech E. Inflammatory bowel disease: current therapeutic options. Digestion 2006;73:67-76.
8. Faubion Jr WA, Loftus Jr EV, Harmsen WS, Zensmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a populationbased study. Gastroenterology 2001;121:255-60. (Pubitemid 32729372)
9. Gohda E, Tsubouchi H, Nakayama H, Hirono S, Sakiyama O, Takahashi K, et al. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 1988;81:414-9. (Pubitemid 18075233)
10. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003;3:81-92. (Pubitemid 36705487)
11. Hasuike S, Ido A, Uto H, Moriuchi A, Tahara Y, Nagata K, et al. Hepatocyte growth factor accelerates the proliferation of hepatic oval cells in a 2-acetylaminofluorene/partial hepatectomy model in rats. J Gastroenterol Hepatol 2005;20:1753-61. (Pubitemid 43961084)
12. Ido A, Tsubouchi H. Translational research to identify clinical applications of hepatocyte growth factor. Hepatol Res 2009;39:739-47.
13. Ido A, Moriuchi A, Kim Il, Numata M, Nagata-Tsubouchi Y, Hasuike S, et al. Pharmacokinetic study of recombinant human hepatocyte growth factor administered in a bolus intravenously or via portal vein. Hepatol Res 2004;30:175-81. (Pubitemid 39654749)
14. Itoh H, Kataoka H, Tomita M, Hamasuna R, Nawa Y, Kitamura N, et al. Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa. Am J Physiol Gastrointest Liver Physiol 2000;278:635-43.
15. Joplin R, Hishida T, Tsubouchi H, Daikuhara Y, Ayres R, Neuberger JM, et al. Human intrahepatic biliary epithelial cells proliferate in vitro in response to human hepatocyte growth factor. J Clin Invest 1992;90:1284-9.
16. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5. (Pubitemid 41025906)
17. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, et al. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000;275:40453-62. (Pubitemid 32064680)
18. Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci U S A 1994;91:4357-61. (Pubitemid 24143432)
19. Kitamura S, Kondo S, Shimomura Y, Isozaki K, Kanayama S, Higashimoto Y, et al. Expression of hepatocyte growth factor and c-met in ulcerative colitis. Inflamm Res 2000;49:320-4.
20. Lukas M. Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis 2010;28:619-24.
21. Macpherson BR, Pfeiffer CJ. Experimental production of diffuse colitis in rats. Digestion 1978;17:135-50. (Pubitemid 8271158)
22. Miyagawa S, Sawa Y, Taketani S, Kawaguchi N, Nakamura T, Matsuura N, et al. Myocardial regeneration therapy for heart failure: hepatycte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002;105:2256-61.
23. Nguyen GC, Harris ML, Dassopoulos T. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2006;8:499-501.
24. Numata M, Ido A, Moriuchi A, Kim Il, Tahara Y, Yamamoto S, et al. Hepatocyte growth factor facilitates the repair of large colonic ulcers in 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats. Inflamm Bowel Dis 2005;11:551-8.
25. Nusrat A, Parkos CA, Bacarra AE, Godowski PJ, Delp-Archer C, Rosen EM, et al. Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium. J Clin Invest 1994;93:2056-65.
26. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48-57.
27. Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001;15:1515-25. (Pubitemid 32912394)
28. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33.
29. Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther 2011;33:23-32.
30. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81.
31. Siegmund B, Rieder F, Albrich S, Wolf K, Bidlingmaier C, Firestein GS, et al. Adnosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther 2001;296:99-105. (Pubitemid 32015066)
32. SunW, Funakoshi H, Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci 2002;22:6537-48. (Pubitemid 35386410)
33. Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T, et al. Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther 2003;307:146-51. (Pubitemid 37151900)
34. Takahashi M, Ota S, Terano A, Yoshiura K, Matsumura M, Niwa Y, et al. Hepatocyte growth factor induces mitogenic reaction to the rabbit gastric epithelial cells in primary culture. Biochem Biophys Res Commun 1993;191:528-34. (Pubitemid 23222668)
35. Tsubouchi H, Niitani Y, Hirono S, Nakayama H, Gohda E, Arakaki N, et al. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay. Hepatology 1991;13:1-5.
36. Tsune I, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Takei Y, et al. Dietary glycine prevents chemical-induced experimental colitis in the rats. Gastroenterology 2003;125:775-85. (Pubitemid 37070695)
37. Yaekawa M, Nakayama S, Ohnuma K, Sakai T, Abe T, Satoh K, et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphogenic study. Am J Respir Crit Care Med 1997;156:1937-44. (Pubitemid 28011805)
38. Yang R, Bunting S, Ko A, Schwall R, Jin H. Hemodynamic effects of scatter factor in conscious rats. J Cardiovasc Pharmacol 1997;30:294-301. (Pubitemid 28006842)